CochLear EPS - Earnings per Share 2023-2024 | CHEOY
CochLear annual and quarterly earnings per share history from 2023 to 2024. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
- CochLear EPS for the quarter ending June 30, 2024 was $0.00, a 0% increase year-over-year.
- CochLear EPS for the twelve months ending June 30, 2024 was $0.00, a 0% increase year-over-year.
- CochLear 2024 annual EPS was $1.78, a 16.03% increase from 2023.
- CochLear 2023 annual EPS was $1.54, a 3.76% decline from 2022.
- CochLear 2022 annual EPS was $1.6, a 16.49% decline from 2021.
| CochLear Annual EPS | |
|---|---|
| 2024 | $1.78 |
| 2023 | $1.54 |
| 2022 | $1.60 |
| 2021 | $1.91 |
| 2020 | $-1.34 |
| 2019 | $1.71 |
| 2018 | $1.65 |
| 2017 | $1.47 |
| 2016 | $1.20 |
| CochLear Quarterly EPS | |
|---|---|
| 2024-06-30 | $0.00 |
| 2023-12-31 | $0.00 |
| 2023-06-30 | $0.00 |
| 2022-06-30 | $0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $11.662B | $1.488B |
| Cochlear Limited provides implantable hearing solutions principally in the Americas, Europe, the Middle East, Africa and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories and Baha bone conduction implants. Cochlear Limited is based in Sydney, Australia. | |||